LARIMAR THERAPEUTICS, INC.

Analyst Reco. Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Real-time Estimate Cboe BZX Other stock markets 19:13:12 01/05/2024 BST			5-day change	1st Jan Change
7.315 ^USD	+6.17%		+12.54%	+59.78%

03-19	North American Morning Briefing : Stock Futures -2-	DJ
03-14	Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Adjusts Price Target on Larimar Therapeutics to $25 From $14, Maintains Buy Rating	02-13	MT
Citigroup Adjusts Price Target on Larimar Therapeutics to $10 From $4.50, Maintains Buy Rating	02-13	MT
JMP Securities Adjusts Price Target on Larimar Therapeutics to $25 From $17, Maintains Market Outperform Rating	02-13	MT
Citigroup Upgrades Larimar Therapeutics to Buy From Neutral, Price Target is $4.50	11-17	MT
Citigroup Cuts Larimar Therapeutics' Price Target to $4.50 From $7, Maintains Neutral Rating	18/05/23	MT
Guggenheim Adjusts Larimar Therapeutics' Price Target to $14 From $12, Keeps Buy Rating	17/05/23	MT
Citigroup Initiates Larimar Therapeutics at Neutral Rating	13/12/22	MT
Guggenheim Starts Larimar Therapeutics at Buy With $12 Price Target	19/10/22	MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $16 from $10, Maintains Market Outperform Rating	19/09/22	MT
William Blair Upgrades Larimar Therapeutics to Outperform From Market Perform	19/09/22	MT
JMP Securities Adjusts Larimar Therapeutics' Price Target to $8 From $30, Maintains Market Outperform Rating	16/02/22	MT
William Blair Downgrades Larimar Therapeutics to Market Perform From Outperform	15/02/22	MT
LARIMAR THERAPEUTICS : JMP Securities Adjusts Price Target on Larimar Therapeutics to $30 From $43, Maintains Market Outperform Rating	26/05/21	MT
LARIMAR THERAPEUTICS : JMP Securities Starts Larimar Therapeutics at Market Outperform with $35 Price Target	10/02/21	MT
LARIMAR THERAPEUTICS : William Blair Initiates Coverage on Larimar Therapeutics With Outperform Rating	01/02/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer